Skip to main content
Erschienen in: International Journal of Hematology 3/2011

01.03.2011 | Original Article

Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review

verfasst von: Yoshiyuki Kurata, Kingo Fujimura, Masataka Kuwana, Yoshiaki Tomiyama, Mitsuru Murata

Erschienen in: International Journal of Hematology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The epidemiology of primary immune thrombocytopenia (ITP) is not well-characterized in the general population. Most published studies, which have included relatively small numbers of ITP patients, have been conducted in England or Scandinavian countries. No epidemiologic data from Asian countries have been published. This study describes the epidemiology of ITP in a Japanese population. We analyzed the database registry of the Ministry of Health, Labour, and Welfare of Japan, and extracted newly diagnosed acute and chronic ITP patients with a platelet count of <100 × 109/L. From 2004 to 2007, 7,774 cases of ITP were reported, giving an overall incidence of 2.16/100,000/year. The incidence differed greatly between males and females, being 1.72 and 2.58, respectively. The median age of the total affected population was 56 years old. In male patients, there was a striking preponderance of boys below 4 years and a very high peak among those aged 75–89 years. In female patients, the number of ITP patients appeared to show a trimodal distribution by age, with the first peak representing patients below 4 years, the second peak those aged 20–34 years, and the third peak those aged 50–89 years. In conclusion, the incidence of ITP in Japan is not markedly different from that of European countries studied to date. This population-based study reveals that, contrary to previously published studies, the maximum age-specific incidence is in the eighth decade.
Literatur
2.
Zurück zum Zitat McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.CrossRefPubMed McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.CrossRefPubMed
3.
Zurück zum Zitat Zaki M, Hassanein AA, Khalil AF. Childhood idiopathic thrombocytopenic purpura: report of 60 cases from Kuwait. J Trop Pediatr. 1990;36:10–3.CrossRefPubMed Zaki M, Hassanein AA, Khalil AF. Childhood idiopathic thrombocytopenic purpura: report of 60 cases from Kuwait. J Trop Pediatr. 1990;36:10–3.CrossRefPubMed
5.
Zurück zum Zitat Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350:620–3.CrossRefPubMed Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350:620–3.CrossRefPubMed
6.
Zurück zum Zitat Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94:909–13.PubMed Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94:909–13.PubMed
7.
Zurück zum Zitat Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, Wesenberg F. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol. 2000;17:551–8.CrossRefPubMed Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, Wesenberg F. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol. 2000;17:551–8.CrossRefPubMed
8.
Zurück zum Zitat Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966–74.CrossRefPubMed Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966–74.CrossRefPubMed
9.
Zurück zum Zitat Takahashi I, Yorimitsu S. Epidemiological aspects of idiopathic thrombocytopenic purpura in Kochi prefecture. Jpn J Clin Hematol. 2004;45:372–7. (in Japanese). Takahashi I, Yorimitsu S. Epidemiological aspects of idiopathic thrombocytopenic purpura in Kochi prefecture. Jpn J Clin Hematol. 2004;45:372–7. (in Japanese).
10.
Zurück zum Zitat Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgård U, Wesenberg F, Jonsson OG, Henter JI. NOPHO ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178–84.CrossRefPubMed Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgård U, Wesenberg F, Jonsson OG, Henter JI. NOPHO ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178–84.CrossRefPubMed
11.
Zurück zum Zitat Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145:235–44.CrossRefPubMed Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145:235–44.CrossRefPubMed
12.
Zurück zum Zitat Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83:83–9.CrossRefPubMed Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83:83–9.CrossRefPubMed
13.
Zurück zum Zitat George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMed George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMed
14.
Zurück zum Zitat Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnord DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMed Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnord DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMed
15.
Zurück zum Zitat Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–80.CrossRefPubMed Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–80.CrossRefPubMed
16.
Zurück zum Zitat Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. Am J Hematol. 2004;75:12–7.CrossRefPubMed Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. Am J Hematol. 2004;75:12–7.CrossRefPubMed
17.
Zurück zum Zitat Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Sem Thromb Hemost. 2001;27:253–67.CrossRef Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Sem Thromb Hemost. 2001;27:253–67.CrossRef
18.
Zurück zum Zitat Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149:855–64.CrossRefPubMed Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149:855–64.CrossRefPubMed
19.
Zurück zum Zitat Doan CA, et al. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med. 1960;53:861–76.CrossRef Doan CA, et al. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med. 1960;53:861–76.CrossRef
20.
Zurück zum Zitat George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill; 1995. p. 1315–55. George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill; 1995. p. 1315–55.
21.
Zurück zum Zitat Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.CrossRefPubMed Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.CrossRefPubMed
Metadaten
Titel
Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review
verfasst von
Yoshiyuki Kurata
Kingo Fujimura
Masataka Kuwana
Yoshiaki Tomiyama
Mitsuru Murata
Publikationsdatum
01.03.2011
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2011
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0791-1

Weitere Artikel der Ausgabe 3/2011

International Journal of Hematology 3/2011 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.